Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.
Collins
D
D
Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Dublin, Ireland. daniellecollins@rcsi.ie
Ridgway
P F
PF
Winter
D C
DC
Fennelly
D
D
Evoy
D
D
D015746:Abdominal Pain / Q000188:drug therapy / Q000209:etiology; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002277:Carcinoma / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D015986:Confounding Factors, Epidemiologic; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D014945:Wound Healing / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab